Total Payments
$5,116
2024 Payments
$1,195
Companies
29
Transactions
243
Medicare Patients
5,428
Medicare Billing
$386,730
Payment Breakdown by Category
Food & Beverage$4,601 (89.9%)
Education$515.17 (10.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,601 | 235 | 89.9% |
| Education | $515.17 | 8 | 10.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $843.13 | 32 | $0 (2024) |
| GENZYME CORPORATION | $606.09 | 32 | $0 (2024) |
| ABBVIE INC. | $471.79 | 36 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $382.66 | 21 | $0 (2024) |
| VYNE Pharmaceuticals Inc. | $321.19 | 22 | $0 (2021) |
| Amgen Inc. | $313.70 | 11 | $0 (2024) |
| Journey Medical Corporation | $251.84 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $237.35 | 14 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $236.89 | 8 | $0 (2024) |
| Allergan, Inc. | $223.12 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,195 | 47 | Amgen Inc. ($268.02) |
| 2023 | $1,585 | 64 | Janssen Biotech, Inc. ($351.41) |
| 2022 | $558.58 | 36 | ABBVIE INC. ($131.30) |
| 2021 | $325.23 | 20 | VYNE Pharmaceuticals Inc. ($138.75) |
| 2020 | $536.70 | 32 | VYNE Pharmaceuticals Inc. ($182.44) |
| 2019 | $356.03 | 17 | Novartis Pharmaceuticals Corporation ($217.70) |
| 2018 | $414.38 | 19 | Allergan Inc. ($146.38) |
| 2017 | $146.04 | 8 | Valeant Pharmaceuticals North America LLC ($60.05) |
All Payment Transactions
243 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $3.86 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.68 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $20.42 | General |
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $39.13 | General |
| 11/14/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $21.53 | General |
| Category: Dermatology | ||||||
| 11/14/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $8.28 | General |
| Category: Inflammation | ||||||
| 10/30/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $5.34 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/23/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: Inflammation | ||||||
| 10/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: IMMUNOLOGY | ||||||
| 09/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $4.05 | General |
| Category: Immunology | ||||||
| 09/04/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Inflammation | ||||||
| 08/28/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $62.85 | General |
| 08/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.90 | General |
| Category: Immunology | ||||||
| 08/21/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Dermatology | ||||||
| 08/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $94.99 | General |
| Category: Immunology | ||||||
| 07/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $4.96 | General |
| Category: Immunology | ||||||
| 06/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $94.99 | General |
| Category: Immunology | ||||||
| 06/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: Immunology | ||||||
| 06/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Immunology | ||||||
| 05/29/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: Inflammation | ||||||
| 05/28/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $5.07 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,446 | 2,794 | $304,884 | $101,970 |
| 2022 | 14 | 1,351 | 2,537 | $281,691 | $90,750 |
| 2021 | 15 | 1,340 | 2,502 | $291,745 | $100,352 |
| 2020 | 16 | 1,291 | 2,261 | $276,555 | $93,659 |
Total Patients
5,428
Total Services
10,094
Medicare Billing
$386,730
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 170 | 213 | $46,808 | $15,894 | 34.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 271 | 408 | $44,619 | $15,146 | 33.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 177 | 244 | $41,724 | $15,030 | 36.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 133 | 152 | $29,906 | $9,507 | 31.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 188 | 259 | $33,743 | $9,135 | 27.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 48 | 64 | $21,248 | $7,754 | 36.5% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 25 | 28 | $16,469 | $6,054 | 36.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 159 | 1,091 | $14,116 | $5,301 | 37.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 53 | 53 | $11,494 | $3,824 | 33.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 83 | 83 | $11,371 | $3,633 | 32.0% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 26 | 32 | $8,220 | $3,034 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 24 | $5,946 | $2,095 | 35.2% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 17 | 18 | $8,514 | $1,722 | 20.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 32 | 43 | $4,191 | $1,605 | 38.3% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 14 | 15 | $3,669 | $1,474 | 40.2% |
| 11200 | Removal of skin tag, 1-15 skin tags | Office | 2023 | 13 | 13 | $2,306 | $727.17 | 31.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 15 | 54 | $540.00 | $35.35 | 6.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 182 | 220 | $49,060 | $16,588 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 183 | 235 | $41,595 | $13,831 | 33.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 262 | 374 | $41,140 | $13,461 | 32.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 174 | 244 | $32,208 | $8,224 | 25.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 113 | 128 | $25,856 | $8,067 | 31.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 37 | 51 | $16,932 | $5,391 | 31.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 149 | 1,013 | $13,501 | $4,629 | 34.3% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 18 | 21 | $12,705 | $4,223 | 33.2% |
About Dr. Norma Magee, MD
Dr. Norma Magee, MD is a Pediatric Dermatology healthcare provider based in Edinburg, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1093906620.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Norma Magee, MD has received a total of $5,116 in payments from pharmaceutical and medical device companies, with $1,195 received in 2024. These payments were reported across 243 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($4,601).
As a Medicare-enrolled provider, Magee has provided services to 5,428 Medicare beneficiaries, totaling 10,094 services with total Medicare billing of $386,730. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Physician Assistant, Dermatology
- Location Edinburg, TX
- Active Since 08/08/2007
- Last Updated 04/03/2024
- Taxonomy Code 207NP0225X
- Entity Type Individual
- NPI Number 1093906620
Products in Payments
- DUPIXENT (Biological) $862.18
- TREMFYA (Drug) $784.75
- COSENTYX (Biological) $362.24
- SKYRIZI (Biological) $318.60
- Otezla (Drug) $313.70
- Sotyktu (Drug) $237.35
- OPZELURA (Drug) $196.58
- ZILXI (Drug) $170.70
- AMZEEQ (Drug) $150.49
- RINVOQ (Biological) $107.55
- Seysara (Drug) $98.66
- TALTZ (Drug) $90.11
- Cimzia (Drug) $74.86
- REMICADE (Biological) $58.38
- Absorica LD (Drug) $48.59
- JUBLIA (Drug) $41.69
- QBREXZA (Drug) $38.76
- ADBRY (Biological) $36.51
- Zoryve (Drug) $35.95
- BOTOX (Biological) $33.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.